Alptekin K.Hafez J.Brook S.Akkaya C.Tzebelikos E.Ucok A.Tallawy H.E.Danaci A.-E.Lowe W.Karayal O.N.2024-07-222024-07-22200902681315http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18868To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients with persistent symptoms or troublesome side effects were switched using one of three 1-week taper/switch strategies as determined by the investigator. Efficacy was assessed using the Brief Psychiatric Rating Scale score, Clinical Global Impression, Positive and Negative Symptom Scale, Montgomery-Åsberg Depression Rating Scale, and the Global Assessment of Functioning Scale, and tolerability by using standard measures of weight change, extrapyramidal symptoms, and laboratory findings. Suboptimal efficacy was the primary reason for switching. The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day. Completer rates were 68, 60, and 86% in the haloperidol, risperidone, and olanzapine pre-switch groups, respectively. At week 12, a switch to ziprasidone resulted in statistically significant improvement from baseline on the Brief Psychiatric Rating Scale score, Clinical Global Impression- Improvement, Positive and Negative Symptom Scale, and Global Assessment of Functioning scales, reduction in extrapyramidal symptoms and a neutral impact on metabolic parameters. Switch from olanzapine and risperidone resulted in weight reduction and from haloperidol in some weight increase. In conclusion, oral ziprasidone of 80-160 mg/day with food was a clinically valuable treatment option for stable patients with schizophrenia or schizoaffective disorder experiencing suboptimal efficacy or poor tolerability with haloperidol, olanzapine, or risperidone. © 2009 Lippincott Williams & Wilkins, Inc.Englishantiparkinson agentanxiolytic agentbenzodiazepinecholinergic receptor blocking agenthaloperidolhypnotic sedative agentlorazepamolanzapinepropranololrisperidoneziprasidonezolpidemadultagedakathisiaanxiety disorderarticlebehavior disorderBrief Psychiatric Rating ScaleClinical Global Impression scaleclinical trialcontrolled clinical trialcontrolled studydizzinessdrug dose reductiondrug dose titrationdrug efficacydrug substitutiondrug tolerabilitydrug withdrawalextrapyramidal symptomfemalefoodheadachehumaninsomniamajor clinical studymalemetabolic parametersMontgomery Asberg Depression Rating Scalemulticenter studynauseaopen studypatient compliancePositive and Negative Syndrome Scalepriority journalrating scaleschizoaffective psychosisschizophreniaside effectsomnolencetreatment durationunspecified side effectweightweight changeweight gainweight reductionArticle10.1097/YIC.0b013e32832c2624